TABLE 1.
Demographic and clinical features of included subjects
| Age (years) | |
| Mean | 41.8 ± 12.1 |
| Range | 18‐68 |
| Age group, no. (%) | |
| 18‐30 years | 14 (18.9) |
| 31‐50 years | 41 (55.4) |
| >50 years | 19 (25.7) |
| Sex male, no. (%) | |
| Female | 45 (59.2) |
| Male | 31 (40.8) |
| BMI (kg/m2) | 22.3 ± 2.8 |
| Smoking status, no. (%) | |
| Current smoker | 8 (11.8) |
| Former smoker | 7 (10.3) |
| Never smoked | 53 (77.9) |
| History of atopy, no. (%) | 20 (27.4) |
| FEV1 % predicted | 88.3 ± 16.4 |
| FEV1/FVC % | 78.5 ± 9.9 |
| Blood eosinophils counts (× 109 per L) | 0.19 ± 0.23 |
| FeNO (ppb) | 26.2 ± 21.6 |
| Anxiety and depression | |
| SAS score | 2.1 ± 0.5 |
| SDS score | 2.1 ± 0.5 |
| AQLQ | 5.8 ± 0.8 |
| ACQ‐5 score | 1.4 ± 0.9 |
Note. Data are presented as mean ± SD or n (%). The ACQ‐5 assesses asthma symptoms in the previous weeks, each of which is scored on a 7‐point scale that ranges from 0 (no impairment) to 6 (maximum impairment) and averaged; a 0.5‐unit change represents the minimal clinically important difference.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FeNO, fractional exhaled nitric oxide; SAS:, self‐rating anxiety scale; SDS, self‐rating depression scale; AQLQ, Asthma Quality‐of‐Life Questionnaire; ACQ‐5, the 5‐point Asthma Control Questionnaire.